Expertise in
46
conditions

Dr. Addison R. Tolentino

Hematology | Oncology
Saint Luke's Hospital Of Kansas City
4321 Washington St Ste 4000, 
Kansas City, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
46
conditions
Saint Luke's Hospital Of Kansas City
4321 Washington St Ste 4000, 
Kansas City, MO 

Overview

Addison Tolentino is a Hematologist and an Oncologist practicing medicine in Kansas City, Missouri.

Dr. Tolentino is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Essential Thrombocythemia, Paget Disease of the Breast, Colorectal Cancer, Lynch Syndrome, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 10 clinical trials. Dr. Tolentino is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MO

Hospital Affiliations

Anderson County Hospital
Saint Luke's East Hospital
Allen County Regional Hospital
Saint Luke's South Hospital
St Lukes Hospital Of Kansas City

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Saint Luke's Hospital of Kansas City
4321 Washington St Ste 4000, Kansas City, MO 64111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Study Phase: Phase 2
Phase II Study of Weekly Vinorelbine and Paclitaxel in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Phase II Study of Weekly Vinorelbine and Paclitaxel in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 26, 2023
Intervention Type: Other, Drug
Study Phase: Phase 2
Phase II Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck
Phase II Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Terminated
Publish Date: September 08, 2023
Intervention Type: Other, Drug
Study Drugs: Capecitabine, Docetaxel
Study Phase: Phase 2
View 6 Less Clinical Trials

7 Total Publications

Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in BRAF V600E-mutated lung adenocarcinoma: a case report.
Successful rechallenge of BRAF/MEK inhibitor with ruxolitinib in BRAF/MEK inhibitor-induced hemophagocytic lymphohistiocytosis like hyperinflammatory syndrome in BRAF V600E-mutated lung adenocarcinoma: a case report.
Journal: Frontiers in oncology
Published: January 24, 2026
Similar Doctors
Expertise in
6
conditions
Dr. Alan S. Gamis
Hematology | Oncology
Expertise in
6
conditions
Dr. Alan S. Gamis
Hematology | Oncology
Referral may be required

Children's Mercy Kansas City

2401 Gillham Rd, 
Kansas City, MO 
 (2.6 miles away)
816-234-3265
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alan Gamis is a Hematologist and an Oncologist practicing medicine in Kansas City, Missouri. Dr. Gamis is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Leukemia, Acute Megakaryoblastic Leukemia, and Bone Marrow Transplant. Dr. Gamis is currently accepting new patients.

Expertise in
132
conditions
Dr. Jaswinder Singh
Hematology | Oncology
Expertise in
132
conditions
Dr. Jaswinder Singh
Hematology | Oncology
Referral may be required

Ascentist Physicians Group

4901 College Blvd, 
Leawood, KS 
 (8.9 miles away)
913-529-1801
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jaswinder Singh is a Hematologist and an Oncologist practicing medicine in Leawood, Kansas. Dr. Singh is highly rated in 132 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Singh is currently accepting new patients.

Expertise in
51
conditions
Expertise in
51
conditions
Referral may be required

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
 (2.9 miles away)
913-588-1227
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Abdulraheem Yacoub is a Hematologist practicing medicine in Fairway, Kansas. Dr. Yacoub is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Myelofibrosis, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Yacoub is board certified in American Board Of Internal Medicine, Hematology - 2012 and American Board Of Internal Medicine, Medical Oncology - 2011. Dr. Yacoub is currently accepting new patients.

Frequently Asked Questions about Dr. Addison R. Tolentino

How do I make an appointment with Dr. Addison R. Tolentino?

You can book an appointment with Dr. Addison R. Tolentino by calling their office at 816-932-3300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Addison R. Tolentino a top-rated expert for Essential Thrombocythemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Addison R. Tolentino is classified as an Distinguished expert for Essential Thrombocythemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Addison R. Tolentino specialize in?

While Dr. Addison R. Tolentino is a Hematology, they have specific expertise in Essential Thrombocythemia, Paget Disease of the Breast, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Addison R. Tolentino participate in research or clinical trials?

Yes. Dr. Addison R. Tolentino has published 7 articles and abstracts on conditions like Essential Thrombocythemia. You can view a list of Dr. Addison R. Tolentino's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Addison R. Tolentino accept my insurance?

Dr. Addison R. Tolentino accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 816-932-3300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tolentino's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 38 Advanced Conditions
    View All 108 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile